MESSAGE
| DATE | 2017-06-12 |
| FROM | From: "APhA's Pharmacy Today"
|
| SUBJECT | Subject: [Hangout - NYLXS] =?utf-8?q?June_12=2C_2017=3A_Opioid_Crisis_Comp?=
|
From hangout-bounces-at-nylxs.com Mon Jun 12 13:06:19 2017
Return-Path:
X-Original-To: archive-at-nylxs.com
Delivered-To: archive-at-nylxs.com
Received: from www.mrbrklyn.com (www.mrbrklyn.com [96.57.23.82])
by mrbrklyn.com (Postfix) with ESMTP id 31F92163F57;
Mon, 12 Jun 2017 13:06:19 -0400 (EDT)
X-Original-To: hangout-at-www.mrbrklyn.com
Delivered-To: hangout-at-www.mrbrklyn.com
Received: by mrbrklyn.com (Postfix, from userid 1000)
id 64951163F56; Mon, 12 Jun 2017 13:06:16 -0400 (EDT)
Resent-From: Ruben Safir
Resent-Date: Mon, 12 Jun 2017 13:06:16 -0400
Resent-Message-ID: <20170612170616.GB26952-at-www.mrbrklyn.com>
Resent-To: hangout-at-mrbrklyn.com
X-Original-To: ruben-at-mrbrklyn.com
Delivered-To: ruben-at-mrbrklyn.com
Received: from mail79-155.us1.msgfocus.com (mail79-155.us1.msgfocus.com
[81.29.79.155]) by mrbrklyn.com (Postfix) with ESMTP id 167B2160876
for ; Mon, 12 Jun 2017 09:52:02 -0400 (EDT)
DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=msgf; d=msgfocus.com;
h=Subject:Message-ID:Reply-To:X-Mailer:To:List-Unsubscribe:From:Date:MIME-Version:Content-Type;
bh=SAFW+vCkUx3m50RLaG8jCNL9e40=;
b=P8sBLhhBaNST2kw5oO/yXIoNZk3ezH+kNkUL4jPIMpp7eDAWkRzJ4UysXTL/FcB87bulvinVcY7I
M22phlZfIrpTEzk+m/FQ6i/B4nWukvUJ8ypobYpxhBLyPsMpk5FYmWpmj8erxBcUqzsTAZ8Z78o7
QsNKVp7GkN2XFuTRK2E=
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=aphanet.org; s=hrs-dkim;
t=1497275521; bh=/fvz9/VSzk93VCXCi6iIiEGuHoxKvKaHkXvZVyLxf6Q=;
h=Subject:Message-ID:Reply-To:X-Mailer:To:List-Unsubscribe:From:
Date:MIME-Version:Content-Type;
b=jTqYLZc7ZKKvwWDQ42o8mX10iMbqSqhfDjfz8cOw2fXvPow94Fp1Tg32om+xyXKlQ
eBE0l5FAiuOwRuXLSMfDboWeiww9kKqCRq1sC42wwUKrOr6mPwR/v0SQjsDCQNW0Y3
EAmb2u+fSHXDAGe9oGTzx1RRrOkHbKisMtxzW4rE=
Message-ID:
X-Mailer: MessageFocus v2 launch
To: ruben-at-mrbrklyn.com
From: "APhA's Pharmacy Today"
Date: Mon, 12 Jun 2017 14:52:01 +0100
MIME-Version: 1.0
Subject: [Hangout - NYLXS] =?utf-8?q?June_12=2C_2017=3A_Opioid_Crisis_Comp?=
=?utf-8?q?licates_GOP=E2=80=99s_Health_Law_Push?=
X-BeenThere: hangout-at-nylxs.com
X-Mailman-Version: 2.1.17
Precedence: list
Reply-To: APhA's Pharmacy Today
List-Id: NYLXS Tech Talk and Politics
List-Unsubscribe: ,
List-Post:
List-Help:
List-Subscribe: ,
Content-Type: multipart/mixed; boundary="===============1236529168=="
Errors-To: hangout-bounces-at-nylxs.com
Sender: "Hangout"
--===============1236529168==
Content-Type: multipart/alternative; boundary="--19B22B36DBE374DE6A2953414C"
----19B22B36DBE374DE6A2953414C
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
Pharmacy Today
http://apha.msgfocus.com/q/17M5Vd9XzezrvlFKijpEuh/wv
jfps-savedate-728
http://apha.msgfocus.com/c/1dDzAWS6y7YS0LggWMePHycks
Banner JUNE 12, 2017 Top Story logo Opioid Crisis Complicates GOP=E2=80=99s=
Health Law Push Wall Street Journal (06/12/17) Nunn, Sharon The nation=E2=
=80=99s worsening opioid crisis has made key Republican senators hesitate t=
o support legislation dismantling major portions of the Affordable Care Act=
(ACA). Several provisions of the ACA allowed millions of Americans seeking=
substance-abuse treatment to gain coverage, including through an expansion=
of the Medicaid health program. But the House bill repealing the ACA, pass=
ed in early May, would roll back that Medicaid expansion beginning in 2020 =
and allow...
http://apha.msgfocus.com/c/1dDzEWdrYRkmYK0sOlDbqwOq3
emerinsulin-160
http://apha.msgfocus.com/c/1dDzIVyNpAFRWIKEFV1x9vqvE
Drugs & Diseases
logo
=E2=96=AA
Seizing on opioid crisis, a drug maker lobbies hard for its product
=E2=96=AA
WHO targets antimicrobial resistance in new essential medicines list
=E2=96=AA
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blocka=
de
=E2=96=AA
Chi-Med steps closer to Chinese pharma first with drug filing
Practice & Trends
logo
=E2=96=AA
Opioid dealers embrace the dark web to send deadly drugs
=E2=96=AA
Pfizer hikes U.S. prices of 91 drugs by average 20% in 2017
=E2=96=AA
Dietary supplement industry outlines new pedigree protocol
=E2=96=AA
Robotic pharmacy to open at Kirkland Cancer Center
Laws, Regs & Rulings
logo
=E2=96=AA
States lead the fight against Trump's contraception rollback
=E2=96=AA
NJ governor approves law expanding pharmacy access to opioid antidote
=E2=96=AA
Lower drug costs still 'absolute priority' for Trump, Price says
News You Can Use
http://apha.msgfocus.com/c/1dDzMUU8Qk1mUHuQxupSSu2Bf
=E2=96=AA
FDA=E2=80=99s new codeine and tramadol warning further restricts use in kids
http://apha.msgfocus.com/c/1dDzQUfuh3mRSGf2p3OeBsEGQ
=E2=96=AA
Misuse and abuse of noncontrolled drugs: It=E2=80=99s not just prescription=
opioids anymore
http://apha.msgfocus.com/c/1dDzUTAPHMImQEZegDcAkrgMr
http://apha.msgfocus.com/c/1dDzYSWb8w3RODJq8cAW3pSS2
=E2=96=AA
FDA approves first generics of atomoxetine (Strattera) for treatment of ADHD
http://apha.msgfocus.com/c/1dDA2ShwzfpmMCtBZLZhMouXD
http://apha.msgfocus.com/c/1dDAaQYdqI6mIzXZIULZelJ8P
=E2=96=AA
The impact of a retail prescription synchronization program on medication a=
dherence
http://apha.msgfocus.com/c/1dDAeQjyRrrRGyIbAuakXkleq
http://apha.msgfocus.com/c/1dDAiPEUiaNmExsns3yGGiXk1
=E2=96=AA
Report of the APhA Stakeholder Conference on Improving Patient Access to In=
jectable Medications
http://apha.msgfocus.com/c/1dDAmP0fIU8RCwczjCX2phzpC
http://apha.msgfocus.com/c/1dDAqOlB9DumAuWLbclo8gbvd
=E2=96=AA
Resource Guide for Immunization Services
http://apha.msgfocus.com/c/1dDAuNGWAmPRytGX2LJJReNAO
junebom
http://apha.msgfocus.com/c/1dDAyN2i16bmwsr8Ul85AdpGp
PT_May2017_Cover
http://apha.msgfocus.com/c/1dDACMnDrPwRurbkLUwrjc1M0
Top Story
Opioid Crisis Complicates GOP=E2=80=99s Health Law Push
Wall Street Journal (06/12/17) Nunn, Sharon
The nation=E2=80=99s worsening opioid crisis has made key Republican senato=
rs hesitate to support legislation dismantling major portions of the Afford=
able Care Act (ACA). Several provisions of the ACA allowed millions of Amer=
icans seeking substance-abuse treatment to gain coverage, including through=
an expansion of the Medicaid health program. But the House bill repealing =
the ACA, passed in early May, would roll back that Medicaid expansion begin=
ning in 2020 and allow insurance companies to charge some people with drug =
addictions higher premiums or deny them substance-abuse coverage. Concerns =
about those provisions cut into Republican support for the replacement meas=
ure in the House. Of the 20 Republicans who voted against the House bill, 1=
6 represent states that saw significant increases in drug-overdose death ra=
tes in recent years. Now, the same concerns are emerging as a factor as the=
Senate takes up the House bill and ponders how to change it. Some Republic=
an senators are pushing to wind down the Medicaid expansion funding more sl=
owly. They would have the rollback occur over a 7-year window beginning in =
2020. Lawmakers are also looking at including a pot of money specifically f=
or opioid treatment, according to Republican senate aides.
Read More
http://apha.msgfocus.com/c/1dDAGLIYSySmspVwDtUN2aDRB | Return to Headlines
Drugs & Diseases
Seizing on opioid crisis, a drug maker lobbies hard for its product
New York Times (06/12/17) Goodnough, Abby; Zernike, Kate
Drug manufacturer Alkermes has spent years targeting lawmakers and law enfo=
rcement strategies, lobbying them about the benefits of its naltrexone (Viv=
itrol) drug as a treatment for opioid addiction. Now, its sales and profile=
are rising fast, thanks to its manufacturers=E2=80=99 shrewd use of politi=
cal connections, and despite scant science to prove the drug=E2=80=99s effi=
cacy. Last month, HHS Secretary Tom Price, praised it as the future of opio=
id addiction treatment after visiting the company=E2=80=99s plant in Ohio. =
He set off a furor among substance abuse specialists by criticizing its les=
s expensive and more widely used and rigorously studied competitors, bupren=
orphine and methadone, as medications that "simply substitute" for illicit =
drugs. With the Trump administration sending $1 billion in new addiction pr=
evention and treatment funds to states over the next 2 years through the 21=
st Century Cures Act, Alkermes's marketing has shifted into even higher gea=
r. Nearly 700 experts in the field recently wrote a letter to Price asserti=
ng that some the company's marketing tactics ignore widely accepted science=
. Alkermes executives say they welcome any addiction treatment. They have p=
resented their drug as a cleaner alternative to buprenorphine.
Read More
http://apha.msgfocus.com/c/1dDAKL4kjidRqoFIv3j8L9fXc | Return to Headlines
WHO targets antimicrobial resistance in new essential medicines list
British Medical Journal (06/09/17) Gulland, Anne
The World Health Organization says the antibiotics colistin and some cephal=
osporins should only be used when all other treatments have failed, in an e=
ffort to combat anti-microbial resistance. In the latest edition of its ess=
ential medicines list, updated every 2 years, WHO has grouped antibiotics i=
nto three groups=E2=80=94access, watch, and reserve=E2=80=94indicating whic=
h can be used for common infections and which should only be used in rare c=
ircumstances. WHO recommends that antibiotics in the access group, which in=
cludes amoxicillin, be available at all times to treat common conditions. T=
he watch group includes antibiotics that are recommended as first or second=
choice treatments for a small number of infections. In this group are cipr=
ofloxacin to treat cystitis and upper respiratory tract infections which, W=
HO says, should be dramatically reduced to avoid further development of res=
istance. The third group, reserve, includes antibiotics that should be cons=
idered last resort options and used only when all other drugs have failed, =
such as for life threatening infections from multidrug resistant bacteria.
Read More
http://apha.msgfocus.com/c/1dDASJL1aKURmma6ec5Qd6u8o | Return to Headlines
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blocka=
de
Science (06/08/17) Le, Dung T.; Durham, Jennifer N.; Smith, Kellie N.; et a=
l.
In a new study, researchers report the expansion of a proof-of-concept stud=
y that found that colorectal cancers with mismatch repair (MMR) deficiency =
were sensitive to immune checkpoint blockade with anti-PD-1 antibodies. The=
new study evaluated the efficacy of PD-1 blockade in patients with advance=
d MMR-deficient cancers for 12 different tumor types. The data show that ob=
jective radiographic responses were seen in more than one-half (53%) of the=
patients, while 21% achieved complete responses. The responses, they note,=
were durable with median progression-free and overall survival still not r=
eached. Functional analysis in a responding patient revealed rapid in vivo =
expansion of neoantigen-specific T cell clones that were reactive to mutant=
neopeptides found in the tumor. According to the researchers, the findings=
"support the hypothesis that the large proportion of mutant neoantigens in=
MMR-deficient cancers make them sensitive to immune checkpoint blockade, r=
egardless of the cancers' tissue of origin."
Read More
http://apha.msgfocus.com/c/1dDAWJ6mBugmkkUi5LubW56dZ | Return to Headlines
Chi-Med steps closer to Chinese pharma first with drug filing
Reuters (06/12/17)
Hutchison China MediTech, the Shanghai-based drugmaker listed in London, re=
ported on Monday that China's Food and Drug Administration will now review =
its cancer medicine fruquintinib as a treatment for advanced colorectal can=
cer. The move triggers a milestone payment of $4.5 million from U.S. partne=
r Eli Lilly to the Chinese firm, which is commonly known as Chi-Med.
Chi-Med and Lilly also aim to win approval for fruquintinib in the United S=
tates, which would make it the first modern drug developed in China to be s=
old on the international market. Hopes for the drug, which starves tumors o=
f blood supply, received a major boost in March when a late-stage clinical =
trial produced strongly positive results in colon cancer. The drug is also =
being developed for non-small cell lung cancer and another study in gastric=
cancer is due to start soon.
Read More
http://apha.msgfocus.com/c/1dDB0IrI2dBRijEtXkSxF3IjA | Return to Headlines
Practice & Trends
Opioid dealers embrace the dark web to send deadly drugs
New York Times (06/11/17) Popper, Nathaniel
In a growing number of arrests and opioid overdoses, law enforcement offici=
als say, the drugs are being bought online. Internet sales have allowed pow=
erful synthetic opioids such as fentanyl to reach people through small pack=
ages in the mail. The authorities have been frustrated in their efforts to =
crack down on the trade because these sites generally exist on the so-calle=
d dark web, where buyers can visit anonymously using special browsers and m=
ake purchases with virtual currencies like Bitcoin. Largely because of thei=
r potency, synthetic opioids have become the fastest-growing cause of the o=
verdose epidemic. Just a few flakes of fentanyl can be fatal. Their deadly =
efficiency also makes them ideal for sale online. Unlike heroin and prescri=
ption opioid analgesics, which are relatively bulky, enough fentanyl to eff=
ect nearly 50,000 people can fit in a standard first-class envelope. The au=
thorities say these markets account for a small proportion of the overall t=
raffic in most drugs. But when it comes to synthetic opioids, many authorit=
ies tracking the traffic say that dark web markets have quickly assumed a m=
ore prominent role.
Read More
http://apha.msgfocus.com/c/1dDB4HN3sWXmgioFOUgTo2kpb | Return to Headlines
Pfizer hikes U.S. prices of 91 drugs by average 20% in 2017
Reuters (06/02/17) Grover, Natalie
Pfizer has increased the list price of 91 medicines in the United States by=
an average of 20% thus far in 2017, according to a new report. Data seen b=
y the Financial Times indicate the company raised the list price of the dru=
gs by 5%=E2=80=9313% on June 1, after also increasing prices in January. A =
company spokesperson noted, "For Pfizer's U.S. biopharma business, as of th=
e first quarter, the weighted average net selling price increase year-to-da=
te is 4%," referring to prices after discounts and rebates, rather than lis=
t prices.
Read More
http://apha.msgfocus.com/c/1dDB8H8oTGiReh8RGtFf70WuM | Return to Headlines
Dietary supplement industry outlines new pedigree protocol
Drug Store News (06/01/17) Johnsen, Michael
The SIDI Work Group=E2=80=94a coalition of the Consumer Healthcare Products=
Association, the Council for Responsible Nutrition (CRN), and the United N=
atural Products Alliance=E2=80=94issued an updated draft of the "Standardiz=
ed Information on Dietary Ingredients Protocol." According to Duffy Mackay,=
chair of the SIDI Work Group executive committee and senior vice president=
, scientific and regulatory affairs, CRN, "The SIDI Work Group convened reg=
ularly over several months developing an updated draft that addresses new f=
ood safety regulations implemented since version 2.1 was released in 2008. =
We welcome comments from industry stakeholders and regulatory officials for=
consideration as we finalize this next edition of the Protocol, slated for=
release by the end of 2017." The Protocol presents an outline representing=
the type and scope of information about a dietary ingredient that an ingre=
dient supplier typically needs to provide to a manufacturer. The primary ob=
jective of the Protocol is to recommend a standard format for presenting th=
is information, so that information exchange can be done in a simplified an=
d streamlined manner. The SIDI Work Group is seeking feedback from industry=
stakeholders and regulators by July 3. The draft Protocol and comment form=
are available here
http://apha.msgfocus.com/c/1dDBcGtKkpEmcfT3y33APZyAn.
Read More
http://apha.msgfocus.com/c/1dDBgFP5L8ZRaeDfpCrWyYaFY | Return to Headlines
Robotic pharmacy to open at Kirkland Cancer Center
Jackson Sun (Tennessee) (05/20/17) Faris, Maranda
The Kirkland Cancer Center in Jackson, TN, recently opened its new robotic =
pharmacy. The pharmacy will allow medications to be mixed more accurately i=
n a liquid form and decrease the amount of waste from other forms of medica=
tion. The new pharmacy also allows more patients to visit the Jackson and t=
he Kirkland Cancer Center, rather than having to go out of state for treatm=
ents. "You don't have to go somewhere else. You may choose to, but there ar=
e many things that you can do right here at home, and this is one of the la=
test advances," West Tennessee Healthcare Foundation President Frank McMeen=
said. "You don't have to go to Houston, or Wisconsin or Ohio. It puts us i=
n a whole other league of cancer facilities." McMeen said the pharmacy is b=
eing named after Eugene Reese, MD, and his wife, Elaine. "The pharmacy has =
become more and more involved in compounding the medicines, mixing them and=
getting them ready for patients to be treated," Reese said. "The pharmacy =
has become a much more important role in the treatment of oncology patients=
than it was 40 years ago."
Read More
http://apha.msgfocus.com/c/1dDBkFarbSlm8dnrhbQihWMLz | Return to Headlines
Laws, Regs & Rulings
States lead the fight against Trump's contraception rollback
New York Times (06/10/17) Stolberg, Sheryl Gay
With the Trump administration planning to roll back the Affordable Care Act=
(ACA) mandate that employers cover contraceptives, the battle over the iss=
ue is shifting to the states. Currently, 28 states have some type of "contr=
aceptive equity" law, aimed at making it cheaper and more accessible. Gov. =
Brian Sandoval of Nevada on June 10 signed a measure requiring insurers to =
cover 12 months of contraception at a time, with no copayment. Several stat=
es are expanding access by requiring insurers to cover a year=E2=80=99s sup=
ply of contraceptives at a time, as opposed to the customary 3 months. In W=
ashington, Gov. Jay Inslee last month signed a bill that would do just that=
, and Gov. John Hickenlooper of Colorado signed a similar bill last week. L=
awmakers in Massachusetts and New York are also considering "contraceptive =
equity bills." The Trump administration has drafted a far-reaching rule tha=
t would greatly expand the number of employers and insurers that could qual=
ify for exemptions from the ACA's contraceptive mandate by claiming a moral=
or a religious objection. Hundreds of thousands of women, many of them poo=
r, could lose access to no-cost birth control if the rule goes into effect.
Read More
http://apha.msgfocus.com/c/1dDBoEvMCBGR6c7D8LeE0VoRa | Return to Headlines
NJ governor approves law expanding pharmacy access to opioid antidote
NJ Spotlight (06/12/17) Stainton, Lilo
Gov. Chris Christie of New Jersey signed a law Friday that would allow phar=
macies of all sizes to sell naloxone, which is easy to administer as a shot=
or nasal spray that can quickly reverse a potentially deadly reaction to h=
eroin or prescription drugs. "Expanding access to nalaxone will help save l=
ives and allow those who are suffering from addiction a second chance to ge=
t the treatment they need to win their battle" with the disease, said Sen. =
Joe Vitale (D-Middlesex), who first introduced a proposal to expand drug st=
ore sales in November 2015. Vitale noted access to the antidote was limited=
in the past, especially for civilians who were not first responders. "But =
the antidote can be administered safely and swiftly by others, including fa=
mily members, and providing access to it at the pharmacy can mean the diffe=
rence between life and death," he said. A growing number of community pharm=
acies, including CVS and Walgreens, announced plans last year to expand sal=
es of the medicine to patients without specific orders from a doctor to hun=
dreds of stores in New Jersey.
The new law makes clear that smaller, independent pharmacies can do the sam=
e, and directs a doctor in the ranks of the state Department of Health to s=
tep in and provide the required standing order if the pharmacy does not hav=
e a physician to do so.
Read More
http://apha.msgfocus.com/c/1dDBsDR83l2m4aRP0kCZJU0WL | Return to Headlines
Lower drug costs still 'absolute priority' for Trump, Price says
Bloomberg (06/08/17) Edney, Anna
HHS Secretary Tom Price, MD, on June 8 told the Senate Finance Committee th=
at President Trump has asked his agency for recommendations on policies tha=
t would reduce the costs of medications. Price said he instructed CMS, FDA,=
and the Health Resources and Services Administration to come up with propo=
sals. He has also been meeting with pharmacists, care providers, and PBMs i=
n recent weeks to discuss ideas for making drugs more affordable. At the Se=
nate hearing, Price declined to answer a separate question about whether th=
e administration will fund cost-sharing reduction payments made to insurers=
to help reduce low-income Americans' health expenses.
Read More
http://apha.msgfocus.com/c/1dDBACxOUNJm08mcJtpHbRf7X | Return to Headlines
Abstract News =C2=A9 Copyright 2017 INFORMATION, INC.
http://apha.msgfocus.com/c/1dDBEBTalx4QY76oB2O2UPRdy
Powered by Information, Inc.
http://apha.msgfocus.com/c/1dDBIBevMgqlW5QAsCcoDOtj9
careerctr-728
http://apha.msgfocus.com/c/1dDBMAzRcZLQU4AMkbAKmN5oK
http://apha.msgfocus.com/c/1dDBQzVcDJ7lS3kYbKZ65LHul
----19B22B36DBE374DE6A2953414C
Content-Type: text/html; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable
"http://www.w3.org/TR/html4/loose.dtd">
Pharmacy Today
width=3D"728">
=20=20=20=20
>=20=20=20=20=20=20=20=20
g=3D0 width=3D"728">
:center;" id=3D"TDLinkBar" bgcolor=3D"#ffffff" valign=3D"top" colspan=3D"2"=
align=3D"center">
vlFKijpEuh/wv">View this email online.
|
=20=20=20=20
inkBar" bgcolor=3D"#ffffff" valign=3D"top" colspan=3D"2">
rOKjzW" target=3D"_blank">![](3D"http://www.infoinc.com/c1/sponsors/ad=<BR) s/JFPS-2017-Save-The-Date-728x90.png" hspace=3D"0" vspace=3D"0" border=3D"0=
" alt=3D"jfps-savedate-728" />
|
![](3D"http://www.infoinc.com/apha_daily/i=<BR) mages/banner.jpg" alt=3D"Banner" width=3D"728" height=3D"190" hspace=3D"0" =
vspace=3D"0" border=3D"0" usemap=3D"#bannerMap">
|
ing=3D"0" border=3D"0">
&=
nbsp;
|
ong>JUNE 12, 2017
|
olspan=3D"2" style=3D"height: 5px;">
|
|
|
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20
" >
ing=3D"0" border=3D"0">
idth=3D"728">
![](3D"http://www.infoinc.com/=<BR) apha_daily/images/top-story.gif" border=3D"0" alt=3D"Top Story" width=3D"72=
8" height=3D"39" />
|
"0" cellpadding=3D"0" border=3D"0">
ign=3D"top" width=3D"350" style=3D"padding: 0px;">
n-bottom:10px;"> ![]() c=3D"http://www.infoinc.com/apha_daily/images/library/1998/laws-3_lg.jpg" a= lt=3D"logo" hspace=3D"0" vspace=3D"0" border=3D"0" style=3D"padding:0px;max= -width:350px;" width=3D"350" />
=20=20=20=20
|
le=3D"padding: 5px;" valign=3D"top" width=3D"378">
O=
pioid Crisis Complicates GOP’s Health Law Push
Wall=
Street Journal (06/12/17) Nunn, Sharon
The nation’s=
worsening opioid crisis has made key Republican senators hesitate to suppo=
rt legislation dismantling major portions of the Affordable Care Act (ACA).=
Several provisions of the ACA allowed millions of Americans seeking substa=
nce-abuse treatment to gain coverage, including through an expansion of the=
Medicaid health program. But the House bill repealing the ACA, passed in e=
arly May, would roll back that Medicaid expansion beginning in 2020 and all=
ow... Read More
=3D"margin-top:5px; line-height: 1.75">
=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20
|
=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20
|
|
|
r=3D"#ffffff" align=3D"left" valign=3D"top" colspan=3D"2">
|
inkBar" bgcolor=3D"#ffffff" width=3D"424">
ing=3D"0" border=3D"0">
g: 0px;">
apha_daily/images/news.gif" width=3D"424" height=3D"31" border=3D"0" alt=3D=
"News You Can Use" />
|
g: 0px;">
pacing=3D"0" cellpadding=3D"0" border=3D"0">
g: 0px;" width=3D"128">
|
g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to=
p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=09
://apha.msgfocus.com/c/1dDC6xiAmEvlJYjJE2yuZG9QJ" target=3D"_blank">![]() c=3D"http://www.infoinc.com/apha_daily/images/pharmacy-today.gif" border=3D=
"0" alt=3D"" />
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20
|
g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20
|
g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to=
p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=09
://apha.msgfocus.com/c/1dDCmuFY5zTlBTiv6k7TTACd7" target=3D"_blank">![]() c=3D"http://www.infoinc.com/apha_daily/images/drug-info-line.gif" border=3D=
"0" alt=3D"" />
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20
|
g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20
|
g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to=
p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=09
://apha.msgfocus.com/c/1dDCutmEX2AlxQMSPsUBlxQoj" target=3D"_blank">![]() c=3D"http://www.infoinc.com/apha_daily/images/japha.gif" border=3D"0" alt=
=3D"" />
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20
|
g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20
|
g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to=
p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=09
://apha.msgfocus.com/c/1dDCCs3lOvhltOhgyBHiNv4zv" target=3D"_blank">![]() c=3D"http://www.infoinc.com/apha_daily/images/Education_Icon.png" border=3D=
"0" alt=3D"" />
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20
|
g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20
|
g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to=
p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=09
://apha.msgfocus.com/c/1dDCKqK2FXYlpLLEhKu0fsiKH" target=3D"_blank">![]() c=3D"http://www.infoinc.com/apha_daily/images/PT_Resources_Icon.png" border=
=3D"0" alt=3D"" />
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20
|
g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20
|
|
|
inkBar" bgcolor=3D"#ffffff" width=3D"300" valign=3D"top">
|
r=3D"#ffffff" align=3D"left" valign=3D"top" colspan=3D"2">
|
=20
inkBar" bgcolor=3D"#ffffff" valign=3D"top">=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=
=20=20=20=20=20=20=20=20=20=20
![](3D"http://www.infoinc.=<BR) com/apha_daily/images/APhA.TopStory.gif" border=3D"0" alt=3D"Top Story" /><=
br>
Opioid Crisis Complicates GOP’s Health Law Push
Wa=
ll Street Journal (06/12/17) Nunn, Sharon
The nation&rsquo=
;s worsening opioid crisis has made key Republican senators hesitate to sup=
port legislation dismantling major portions of the Affordable Care Act (ACA=
). Several provisions of the ACA allowed millions of Americans seeking subs=
tance-abuse treatment to gain coverage, including through an expansion of t=
he Medicaid health program. But the House bill repealing the ACA, passed in=
early May, would roll back that Medicaid expansion beginning in 2020 and a=
llow insurance companies to charge some people with drug addictions higher =
premiums or deny them substance-abuse coverage. Concerns about those provis=
ions cut into Republican support for the replacement measure in the House. =
Of the 20 Republicans who voted against the House bill, 16 represent states=
that saw significant increases in drug-overdose death rates in recent year=
s. Now, the same concerns are emerging as a factor as the Senate takes up t=
he House bill and ponders how to change it. Some Republican senators are pu=
shing to wind down the Medicaid expansion funding more slowly. They would h=
ave the rollback occur over a 7-year window beginning in 2020. Lawmakers ar=
e also looking at including a pot of money specifically for opioid treatmen=
t, according to Republican senate aides.
=20
com/apha_daily/images/drugs-diseases.gif" border=3D"0" alt=3D"Drugs & Disea=
ses" />
Seizing on opioid crisis, a drug maker lobbies hard for its productb>
New York Times (06/12/17) Goodnough, Abby; Zernike, Kate />
Drug manufacturer Alkermes has spent years targeting lawmakers a=
nd law enforcement strategies, lobbying them about the benefits of its nalt=
rexone (Vivitrol) drug as a treatment for opioid addiction. Now, its sales =
and profile are rising fast, thanks to its manufacturers’ shrewd use =
of political connections, and despite scant science to prove the drug&rsquo=
;s efficacy. Last month, HHS Secretary Tom Price, praised it as the future =
of opioid addiction treatment after visiting the company’s plant in O=
hio. He set off a furor among subs |
|
 |
|
|
|
 |
|
|
